- THE MAGAZINE
- INFO FOR...
- ASI Store
- ASI Top 25
- Product & Literature Showcases
- Services Marketplace
- List Rental
- Market Trends
- Custom Content & Marketing Services
- ASI Readers' Choice Awards
The acquisition of Chemir reportedly allows EAG to better serve the industry-specific needs of its diverse clients. This includes medical device and pharmaceutical companies that require FDA testing beyond materials characterization and clients seeking to develop novel coating technologies beyond surface analysis investigations.
“With this acquisition, we are excited that EAG can deliver our elite services to customers across a broader range of analytical, test and development offerings,” said Harry Davoody, CEO of EAG. “The combination of our companies and integrated scope of services means EAG is a stronger partner for our clients, enabling them to more effectively achieve their time-to-market or solutions goals.”
For more information, visit www.eaglabs.com, www.cas-mi.com or www.chemir.com.